Evogene Cuts Expenses 37% to $13.8M but Sees Revenue Drop to $3.9M
Evogene cut operating expenses to $13.8 million in 2025 from $22 million in 2024 and swung discontinued operations income to $5.7 million versus a $3.2 million loss. Full-year revenue dropped to $3.9 million from $5.6 million driving a $7.8 million net loss despite Bayer, Corteva and Google Cloud AI collaborations.
1. Operational Restructuring and Expense Reduction
Evogene streamlined operations by divesting non-core activities and resizing its workforce, cutting operating expenses from $22 million in 2024 to $13.8 million in 2025. General and administrative costs fell to $4.3 million and sales and marketing expenses declined to $1.5 million.
2. Revenue Declines and Impairment
Full-year revenue fell to $3.9 million from $5.6 million year-over-year, driven by lower AgPlenus activity and a Q4 slump to $0.3 million. The company recorded a $2.2 million impairment on Casterra’s seed inventory, contributing to a net loss of $7.8 million.
3. Strategic Partnerships and AI Initiatives
Evogene expanded human health and agriculture alliances with Bayer and Corteva and launched a second collaboration with Google Cloud to deploy advanced AI agents. The firm is concentrating resources on its ChemPass generative AI engine to enhance small-molecule discovery in pharmaceuticals and crop chemicals.
4. Cash Position and Future Catalysts
The company generated $5.7 million from discontinued operations compared to a $3.2 million loss last year and expects Lavie Bio and MicroBoost sale proceeds to fund operations through mid-2026. Management highlighted upcoming BMC128 licensing milestones with Lishan Pharmaceuticals and further ChemPass AI collaboration agreements as potential catalysts.